299 related articles for article (PubMed ID: 23806556)
1. Rational design and generation of recombinant control reagents for bispecific antibodies through CDR mutagenesis.
Choi BD; Gedeon PC; Kuan CT; Sanchez-Perez L; Archer GE; Bigner DD; Sampson JH
J Immunol Methods; 2013 Sep; 395(1-2):14-20. PubMed ID: 23806556
[TBL] [Abstract][Full Text] [Related]
2. A Combination of Structural and Empirical Analyses Delineates the Key Contacts Mediating Stability and Affinity Increases in an Optimized Biotherapeutic Single-chain Fv (scFv).
Tu C; Terraube V; Tam AS; Stochaj W; Fennell BJ; Lin L; Stahl M; LaVallie ER; Somers W; Finlay WJ; Mosyak L; Bard J; Cunningham O
J Biol Chem; 2016 Jan; 291(3):1267-76. PubMed ID: 26515064
[TBL] [Abstract][Full Text] [Related]
3. CDR-restricted engineering of native human scFvs creates highly stable and soluble bifunctional antibodies for subcutaneous delivery.
Fennell BJ; McDonnell B; Tam AS; Chang L; Steven J; Broadbent ID; Gao H; Kieras E; Alley J; Luxenberg D; Edmonds J; Fitz LJ; Miao W; Whitters MJ; Medley QG; Guo YJ; Darmanin-Sheehan A; Autin B; Shúilleabháin DN; Cummins E; King A; Krebs MR; Grace C; Hickling TP; Boisvert A; Zhong X; McKenna M; Francis C; Olland S; Bloom L; Paulsen J; Somers W; Jensen A; Lin L; Finlay WJ; Cunningham O
MAbs; 2013; 5(6):882-95. PubMed ID: 23995618
[TBL] [Abstract][Full Text] [Related]
4. Grabbing the Bull by Both Horns: Bovine Ultralong CDR-H3 Paratopes Enable Engineering of 'Almost Natural' Common Light Chain Bispecific Antibodies Suitable For Effector Cell Redirection.
Klewinghaus D; Pekar L; Arras P; Krah S; Valldorf B; Kolmar H; Zielonka S
Front Immunol; 2021; 12():801368. PubMed ID: 35087526
[TBL] [Abstract][Full Text] [Related]
5. A tetravalent bispecific TandAb (CD19/CD3), AFM11, efficiently recruits T cells for the potent lysis of CD19(+) tumor cells.
Reusch U; Duell J; Ellwanger K; Herbrecht C; Knackmuss SH; Fucek I; Eser M; McAleese F; Molkenthin V; Gall FL; Topp M; Little M; Zhukovsky EA
MAbs; 2015; 7(3):584-604. PubMed ID: 25875246
[TBL] [Abstract][Full Text] [Related]
6. CDR loop interactions can determine heavy and light chain pairing preferences in bispecific antibodies.
Fernández-Quintero ML; Kroell KB; Grunewald LJ; Fischer AM; Riccabona JR; Liedl KR
MAbs; 2022; 14(1):2024118. PubMed ID: 35090383
[TBL] [Abstract][Full Text] [Related]
7. Fab-based bispecific antibody formats with robust biophysical properties and biological activity.
Wu X; Sereno AJ; Huang F; Lewis SM; Lieu RL; Weldon C; Torres C; Fine C; Batt MA; Fitchett JR; Glasebrook AL; Kuhlman B; Demarest SJ
MAbs; 2015; 7(3):470-82. PubMed ID: 25774965
[TBL] [Abstract][Full Text] [Related]
8. A Rationally Designed Fully Human EGFRvIII:CD3-Targeted Bispecific Antibody Redirects Human T Cells to Treat Patient-derived Intracerebral Malignant Glioma.
Gedeon PC; Schaller TH; Chitneni SK; Choi BD; Kuan CT; Suryadevara CM; Snyder DJ; Schmittling RJ; Szafranski SE; Cui X; Healy PN; Herndon JE; McLendon RE; Keir ST; Archer GE; Reap EA; Sanchez-Perez L; Bigner DD; Sampson JH
Clin Cancer Res; 2018 Aug; 24(15):3611-3631. PubMed ID: 29703821
[No Abstract] [Full Text] [Related]
9. A novel glycoengineered bispecific antibody format for targeted inhibition of epidermal growth factor receptor (EGFR) and insulin-like growth factor receptor type I (IGF-1R) demonstrating unique molecular properties.
Schanzer JM; Wartha K; Croasdale R; Moser S; Künkele KP; Ries C; Scheuer W; Duerr H; Pompiati S; Pollman J; Stracke J; Lau W; Ries S; Brinkmann U; Klein C; Umana P
J Biol Chem; 2014 Jul; 289(27):18693-706. PubMed ID: 24841203
[TBL] [Abstract][Full Text] [Related]
10. Stability engineering of scFvs for the development of bispecific and multivalent antibodies.
Miller BR; Demarest SJ; Lugovskoy A; Huang F; Wu X; Snyder WB; Croner LJ; Wang N; Amatucci A; Michaelson JS; Glaser SM
Protein Eng Des Sel; 2010 Jul; 23(7):549-57. PubMed ID: 20457695
[TBL] [Abstract][Full Text] [Related]
11. Engineering of stable bispecific antibodies targeting IL-17A and IL-23.
Mabry R; Lewis KE; Moore M; McKernan PA; Bukowski TR; Bontadelli K; Brender T; Okada S; Lum K; West J; Kuijper JL; Ardourel D; Franke S; Lockwood L; Vu T; Frank A; Appleby MW; Wolf A; Reardon B; Hamacher NB; Stevens B; Lewis P; Lewis KB; Gilbertson DG; Lantry M; Julien SH; Ostrander C; Chan C; Byrnes-Blake K; Brody J; Presnell S; Meengs B; Levin SD; Snavely M
Protein Eng Des Sel; 2010 Mar; 23(3):115-27. PubMed ID: 20022918
[TBL] [Abstract][Full Text] [Related]
12. Generation and characterization of monospecific and bispecific hexavalent trimerbodies.
Blanco-Toribio A; Sainz-Pastor N; Álvarez-Cienfuegos A; Merino N; Cuesta ÁM; Sánchez-Martín D; Bonet J; Santos-Valle P; Sanz L; Oliva B; Blanco FJ; Álvarez-Vallina L
MAbs; 2013; 5(1):70-9. PubMed ID: 23221741
[TBL] [Abstract][Full Text] [Related]
13. Arginine mutations in antibody complementarity-determining regions display context-dependent affinity/specificity trade-offs.
Tiller KE; Li L; Kumar S; Julian MC; Garde S; Tessier PM
J Biol Chem; 2017 Oct; 292(40):16638-16652. PubMed ID: 28778924
[TBL] [Abstract][Full Text] [Related]
14. Effect of domain order on the activity of bacterially produced bispecific single-chain Fv antibodies.
Kipriyanov SM; Moldenhauer G; Braunagel M; Reusch U; Cochlovius B; Le Gall F; Kouprianova OA; Von der Lieth CW; Little M
J Mol Biol; 2003 Jun; 330(1):99-111. PubMed ID: 12818205
[TBL] [Abstract][Full Text] [Related]
15. Epitope distance to the target cell membrane and antigen size determine the potency of T cell-mediated lysis by BiTE antibodies specific for a large melanoma surface antigen.
Bluemel C; Hausmann S; Fluhr P; Sriskandarajah M; Stallcup WB; Baeuerle PA; Kufer P
Cancer Immunol Immunother; 2010 Aug; 59(8):1197-209. PubMed ID: 20309546
[TBL] [Abstract][Full Text] [Related]
16. Cytotoxic enhancement of a bispecific diabody by format conversion to tandem single-chain variable fragment (taFv): the case of the hEx3 diabody.
Asano R; Ikoma K; Shimomura I; Taki S; Nakanishi T; Umetsu M; Kumagai I
J Biol Chem; 2011 Jan; 286(3):1812-8. PubMed ID: 21097496
[TBL] [Abstract][Full Text] [Related]
17. Generation of dual-variable-domain immunoglobulin molecules for dual-specific targeting.
Gu J; Ghayur T
Methods Enzymol; 2012; 502():25-41. PubMed ID: 22208980
[TBL] [Abstract][Full Text] [Related]
18. Decomposing Dynamical Couplings in Mutated scFv Antibody Fragments into Stabilizing and Destabilizing Effects.
Ettayapuram Ramaprasad AS; Uddin S; Casas-Finet J; Jacobs DJ
J Am Chem Soc; 2017 Dec; 139(48):17508-17517. PubMed ID: 29139290
[TBL] [Abstract][Full Text] [Related]
19. Anti-tumor activity of stability-engineered IgG-like bispecific antibodies targeting TRAIL-R2 and LTbetaR.
Michaelson JS; Demarest SJ; Miller B; Amatucci A; Snyder WB; Wu X; Huang F; Phan S; Gao S; Doern A; Farrington GK; Lugovskoy A; Joseph I; Bailly V; Wang X; Garber E; Browning J; Glaser SM
MAbs; 2009; 1(2):128-41. PubMed ID: 20061822
[TBL] [Abstract][Full Text] [Related]
20. Immunotherapy based on bispecific T-cell engager with hIgG1 Fc sequence as a new therapeutic strategy in multiple myeloma.
Zou J; Chen D; Zong Y; Ye S; Tang J; Meng H; An G; Zhang X; Yang L
Cancer Sci; 2015 May; 106(5):512-21. PubMed ID: 25664501
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
